2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole

6 trials 5 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

5 Recruiting

1 Completed trials

5 Sponsors

3 Countries

Phase II

Phase II: 6

Indications tested

Dementia 1 Prodromal Alzheimer's disease 1 Neurodegenerative disorder 1 Dementia with Lewy bodies 1 Dementia Alzheimer's type 1 Progressive supranuclear palsy 1

Sponsors using this IMP

Region Skane 2 Barcelonabeta Brain Research Center 1 Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau 1 Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience 1 Vaestra Goetalandsregionen 1

All trials

6 total

Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population Recruiting

2024-516209-21-00 Phase II 1 country Barcelonabeta Brain Research Center
NeuroPET GBG 001 - Mapping pathogenic processes associated with the development of neurodegenerative disorders using novel neuroimaging moda… Recruiting

2024-513499-16-00 Phase II 1 country Vaestra Goetalandsregionen
Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) Recruiting

2023-510508-31-01 Phase II 1 country Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
Positron emission tomography (PET) of patients with brain injury and athletes with concussion symptoms - Descriptive study of the tau tracer… Recruiting

2024-517048-67-00 Phase II 1 country Region Skane
The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Recruiting

2024-511842-38-00 Phase II 1 country Region Skane
Impact of microglial activation on synaptic density in Alzheimer’s disease Ended

2024-516566-11-00 Phase II 1 country Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Showing 1–6 of 6 trials

← All drugs A–Z